Summary:
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of study medication in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
Qualified Participants Must:
• Be 18 Years to 75 Years
•
Has previously been documented to have met or currently meets Systemic Lupus International Collaborating Clinics (SLICC) and/or American College of Rheumatology (ACR) criteria for SLE
•
Received at least 1 immunosuppressive or immunomodulatory treatment for SLE at any time in the past or currently
Qualified Participants May Receive:
May be eligible to receive reimbursement for time and travel for study participation, if you qualify.